efficacy of pegaptanib sodium (macugen) on uveitic cystoid macular oedema: an exploratory study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-000705-30-GB

Enrollment

Registered

2007-03-28

Start date

2007-05-15

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uveitic cystoid macular oedema MedDRA version: 9.1 Level: LLT Classification code 10058202 Term: Cystoid macular oedema

Interventions

Trade Name: Macugen Pharmaceutical Form: Solution for injection Other descriptive name: PEGAPTANIB SODIUM Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.9-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: all patients with otherwise controlled uveitis that present a persistent cystoid macular oedema Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: active intraocular inflammation cystoid macular oedema treated with periocular / intraocular steroids less than 3 months pregnant women children

Design outcomes

Primary

Measure	Time frame
Main Objective: to treat pesistent uveitic cystoid macular oedema measured by reduction of macular thickness;Secondary Objective: to improve visual acuity;Primary end point(s): to achieve post-injection reduction of macular thickness, measured by optical coherence tomography	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026